Table 3.

Vansteelandt modeling for mediation of time to first MACE with liraglutide versus placebo: by HbA_1c, body weight, UACR, SBP, LDL cholesterol, confirmed hypoglycemic episodes, SU use, and insulin use

Variable	Estimated proportion of patients without MACE at 3 years			Percentage mediation (95% CI)
	Liraglutide	Liraglutide, adjusted for candidate mediator	Placebo
HbA1c	0.893	0.881	0.878	82.0 (11.7; 449.3)
Body weight	0.893	0.891	0.879	14.3
UACR	0.892	0.888	0.880	33.3
Confirmed hypoglycemia	0.893	0.892	0.878	6.7
SBP	0.893	0.891	0.878	13.3
LDL cholesterol	0.893	0.893	0.879	0.0
Insulin use	0.892	0.890	0.878	14.3
SU use	0.893	0.891	0.878	13.3

SBP, systolic blood pressure; SU, sulfonylurea.